Saturday 17 October 2026
Export INMB’s income statement to Excel — free account
INmune Bio, Inc.
INMB Healthcare Biotechnology
INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024. In the quarter to June 2026, revenue grew 8.70%, EPS grew 95.2% and free cash flow grew 55.4%, each against the same quarter a year earlier.
1.57
0.08
−4.85%
Follow INMB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 4 | 2 | 3 | 4 |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | 63.63 | 4.09 | 1.33 | 1.94 | (1.37) | (10.46) |
P/S ratio |
— | — | — | — | 0.00 | 857.41 | 321.63 | 1,301.59 | 710.98 | 286.09 |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 20.28 | 5.37 | 1.46 | (5.96) | (13.61) | (23.75) |
P/Operating CF |
— | — | — | — | (86.30) | (16.82) | (21.12) | (59.32) | (8.46) | (13.12) |
Beneish M-Score |
— | — | — | — | — | 9.40 | (2.03) | (5.11) | (0.93) | (3.67) |
P/B ratio |
— | — | — | — | 5.33 | 2.05 | 2.00 | 5.40 | 2.90 | 1.64 |
Price to Tangible BV |
— | — | — | — | 9.28 | 2.58 | 2.76 | 9.69 | 5.98 | 5.51 |
EV/Sales |
— | — | — | — | 0.00 | 543.28 | 221.48 | 1,149.65 | 588.45 | 138.83 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (20.64) | (3.66) | (3.65) | (14.87) | (2.31) | (0.83) |
EV/FCF |
— | — | — | — | (20.64) | (3.66) | (3.65) | (14.87) | (2.31) | (0.79) |
Quick Ratio |
0.67 | 5.48 | 1.01 | 10.91 | 13.38 | 18.42 | 5.55 | 2.07 | 3.09 | 3.48 |
Current Ratio |
0.75 | 6.13 | 1.03 | 11.09 | 13.51 | 18.95 | 5.92 | 2.16 | 3.14 | 3.55 |
Net Debt/EBITDA |
0.00 | 1.40 | 0.02 | 0.88 | 1.78 | 2.08 | 1.46 | 0.88 | 0.49 | 0.52 |
Debt/Assets |
77.50% | 0.00% | 0.00% | 0.69% | 0.39% | 14.54% | 17.97% | 17.40% | 0.00% | 0.00% |
Debt/Equity |
(2.35) | 0.00 | 0.00 | 0.01 | 0.00 | 0.18 | 0.24 | 0.27 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.14 | 0.92 | 0.17 | 0.70 | 0.74 | 0.94 | 0.83 | 0.40 | 0.79 | 0.49 |
Capex/Depreciation |
— | 0.00 | — | — | — | (119.05) | 0.00 | 0.00 | 0.00 | (12.40) |
| (3.09%) | (9.26%) | (71.82%) | (38.25%) | (38.80%) | (51.00%) | (38.91%) | (61.59%) | (121.21%) | (165.16%) | |
| (2.94%) | (8.82%) | (69.54%) | (36.71%) | (37.16%) | (43.16%) | (30.04%) | (43.24%) | (87.16%) | (127.75%) | |
ROIC |
0.00% | (3.67%) | (47.54%) | (28.88%) | (45.10%) | (91.35%) | (71.62%) | (162.87%) | (238.53%) | 0.00% |
Return on Tangible Assets |
185.99% | (52.30%) | (48,784.31%) | (105.82%) | (54.10%) | (38.42%) | (50.31%) | (139.72%) | (272.53%) | (204.82%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 59,694.09 | 11,099.23 | 8,257.39 | 5,750.52 | 36,734.64 | 33,149.30 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 53,800.00% | 11,349.72% | 4,563.37% | 13,079.35% | 236,900.00% | 41,318.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 57,463.64% | 4,856.91% | 2,475.40% | 6,208.39% | 67,735.71% | 20,520.00% |
Intangible Assets out of Total Assets |
0.00 | 0.90 | 0.95 | 0.67 | 0.41 | 0.17 | 0.20 | 0.29 | 0.42 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 28,290.91% | 2,649.72% | 1,911.50% | 4,753.55% | 54,321.43% | 19,820.00% |
Graham Net Nets |
— | — | — | — | 0.11 | 0.38 | 0.36 | 0.10 | 0.16 | 0.55 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (5.75%) | (18.24%) | (22.65%) | (14.88%) | (45.18%) | (121.79%) |
Free Cash Flow Yield |
— | — | — | — | (4.33%) | (17.32%) | (18.86%) | (5.94%) | (35.82%) | (61.17%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 |
Operating CF per Share |
(0.03) | (0.12) | (0.24) | (0.52) | (0.75) | (1.77) | (1.27) | (0.67) | (1.67) | (0.91) |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | 0.00 | (0.93) | 0.00 | 0.00 | 0.00 | (0.04) |
Free Cash Flow per Share |
(0.03) | (0.13) | (0.24) | (0.52) | (0.75) | (2.70) | (1.27) | (0.67) | (1.67) | (0.95) |
Cash per Share |
0.01 | 0.21 | 0.02 | 0.68 | 1.83 | 4.64 | 2.91 | 1.99 | 1.05 | 1.00 |
Shareholders Equity per Share |
(0.01) | 2.76 | 1.91 | 2.30 | 3.23 | 4.97 | 3.35 | 2.08 | 1.61 | 0.95 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.01) | 2.76 | 1.91 | 2.30 | 3.23 | 4.97 | 3.35 | 2.08 | 1.61 | 0.95 |
Free Cash Flow |
(0.32) | (0.86) | (2.06) | (5.38) | (8.94) | (43.50) | (22.69) | (11.98) | (33.36) | (23.62) |
Working Capital |
(0.15) | 1.59 | 0.03 | 7.06 | 22.21 | 78.25 | 53.76 | 21.48 | 15.44 | 21.47 |
Capital Expenditures |
— | (0.10) | — | — | — | (15.00) | — | — | — | (1.04) |
Net Current Asset Value |
(0.15) | 1.59 | 0.03 | 6.90 | 22.08 | 62.89 | 42.98 | 20.28 | 15.20 | 21.06 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | — | — | 0.00 | 82.87 | 0.00 | 0.00 | 0.00 | 20.84 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | — | 0.00 | 0.00 | 0.17 | 0.47 | 0.00 | 0.00 | 0.09 |
Cash ROIC |
(92.67%) | (4.43%) | (12.31%) | (17.50%) | (14.69%) | (25.66%) | (17.87%) | (14.41%) | (62.92%) | (48.94%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 0.05 | 0.03 | 0.01 | 0.02 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.29 | 0.29 | 0.49 | 0.65 | 1.22 | 3.65 | 6.98 | 5.45 | 1.93 | 2.98 |
Average Payables |
0.27 | 0.27 | 0.57 | 0.76 | 1.12 | 2.68 | 4.51 | 6.58 | 7.25 | 7.18 |
Average Assets |
9.43 | 9.43 | 17.89 | 20.92 | 32.56 | 70.30 | 90.87 | 69.40 | 48.28 | 35.96 |
Average Common Equity |
8.98 | 8.98 | 17.32 | 20.07 | 31.18 | 59.49 | 70.16 | 48.72 | 34.72 | 27.81 |
Columns are period end dates